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Summary
Objective: To investigate changes in levels of serum cartilage oligomeric matrix protein (COMP) and urine c-telopeptide of type-2 collagen
(CTX-II) as markers for cartilage turnover in patients with osteoarthritis (OA) of the knee, in response to muscle strength training in combination
with treatment with glucosamine, ibuprofen or placebo.
Design: A 12-week double blind, placebo controlled, randomized study.
Method: Thirty-six elderly patients with bilateral tibiofemoral knee OA determined by radiography were randomly assigned to treatment with
glucosamine (n¼ 12), ibuprofen (n¼ 12) or placebo (n¼ 12) during 12 weeks of strength training of both legs with focus on the quadriceps
muscle. Strength tests (5 repetition maximum), blood and urine sampling were performed before and after the training period. Serum COMP
and urinary CTX-II were measured by enzyme-linked immunosorbent assay (ELISA).
Results: All three groups increased their muscle strength following 12 weeks of strength training (P< 0.001). Serum COMP levels were re-
duced in the glucosamine-treated group after the training period (P¼ 0.012), whereas they did not change in the two other groups. Glucos-
amine reduced COMP statistically signiﬁcant compared to both placebo and ibuprofen; the mean reduction with glucosamine was 13% vs
placebo (P¼ 0.0378) and 17% vs ibuprofen (P¼ 0.0122).
Urinary CTX-II levels did not change signiﬁcantly in any of the three experimental groups.
Conclusion: Serum COMP decreased signiﬁcantly over the 12-week training period when treatment with glucosamine was added to the train-
ing regimen. This suggests an effect by glucosamine on the response of the OA cartilage to a period of joint loading in humans with knee OA.
ª 2009 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Approximately 8e10% of all men and women have osteoar-
thritis (OA) in one or more of their joints, which causes dis-
ability, pain and reduced quality of life1. The disease
affects the cartilage, synovium, subchondral bone, tendons
and muscles surrounding the joint. There are a number of
established risk factors for OA in the knee such as age, in-
creased body mass index (BMI), previous injury or surgery
of the knee, and genetic factors. Studies also suggest that1Trial Registration: Clinical Trials.gov Identiﬁer: NCT00833157.
*Address correspondence and reprint requests to: Dr Susanne G.
Petersen, Institute of Sports Medicine Copenhagen and Center for
Healthy Aging, Faculty of Health Sciences, Building 8, Bispebjerg
Hospital, Bispebjerg Bakke 23, DK-2400 Copenhagen NV,
Denmark. Tel: 45-35-31-39-48; Fax: 45-35-31-27-33; E-mail:
sp12@bbh.regionh.dk
Received 2 February 2009; revision accepted 8 July 2009.
34reduced quadriceps strength is a risk factor as well as a con-
sequence of OA in the knee2e5. It has repeatedly been
shown, that exercise reduces pain and improves function in
subjects with OA of the knee6e9. These beneﬁcial effects
are seen in protocols including both strength and endurance
training10e17. To our knowledge, it is not known whether
physical training affects cartilage homeostasis in these
patients.
Cartilage oligomeric matrix protein (COMP) is a prominent
component of cartilage matrix18. This glycoprotein has
a role in governing assembly of type II collagen ﬁbres in car-
tilage, and in cooperation with other matrix proteins it stabi-
lizes the collagen network19,20. Patients with knee OA have
increased serum concentrations of COMP21e27. Further-
more, studies suggest that increased levels of serum
COMP are related to progressive joint damage in knee
OA measured by radiography over a 5-year period28,29.
COMP levels are also modiﬁed in response to acute exer-
cise; an acute bout of exercise elevates serum COMP in
35Osteoarthritis and Cartilage Vol. 18, No. 1healthy adults30,31 as well as in patients with knee OA25,
whereas 6 weeks of chronic training did not inﬂuence the
circulating levels of COMP25.
Urinary level of c-telopeptide of type-2 collagen (CTX-II)
is a putative marker of collagen degradation, and found to
be increased in OA patients32e35. Moreover, in patients
with established knee or advanced hip OA, serum CTX-II
is associated with radiological progression over short-term
periods34,36. Also a long-term study over 5 years shows
that progression of OA is associated with increased urinary
CTX-II37. Finally, a study of young, healthy athletes shows
that sport activities such as running signiﬁcantly increase
urinary CTX-II levels, while activities like swimming do not
affect levels of this marker38.
OA is often treated with non-steroidal anti-inﬂammatory
drugs (NSAIDs) or glucosamine1,6,39e41. These treatments
may relieve pain, but their effects on cartilage and syno-
vium metabolism in patients with OA are controversial42,43.
In vitro studies have suggested that NSAIDs may reduce or
increase44e47 the synthesis of cartilage proteoglycans.
Very few studies have examined the effects of NSAIDs or
glucosamineonCTX-II levels inOApatients33,48e50. It seems
that only one pilot study has examined the effect of NSAID
(Nimesulide) on serum COMP levels in OA patients51. To
our knowledge, no studies have yet investigated the effect
of glucosamine on serum COMP levels in OA patients.
The purpose of this study was to investigate, whether 12
weeks of muscle strength training in combination with treat-
ment with glucosamine or ibuprofen (an NSAID), affects
levels of serum COMP (primary outcome) and urinary
CTX-II (secondary outcome), as indicators of cartilage turn-
over, in patients with OA of the knee. A placebo-group was
included for control.
MethodsDESIGNA12-weekdoubleblind, placebocontrolled, randomizedstudy of adultswith
OA of the knee. Staff personnel not involved in the project randomly assigned
patients to the three groups using a randomnumber table, and other personnel
prepared the medication for each patient. All study personnel and participants
were blinded to treatment assignment for the duration of the study.PARTICIPANTS AND CRITERIAFig. 1. Time-schedule.Todetect changes in levels of serumCOMPof 10%ormoreat a signiﬁcance
level of 0.05 with a power of 0.8, and taking into account the inter- and intra-in-
dividual variation as well as variation in themethods, approximately 10 individ-
uals were required in each group. In total 36 patients (20 women, 16 men);
aged 50e70 yearswith bilateral tibiofemoralOAof the knee, basedupon radio-
graphs, were recruited in the period January 2005 to January 2006 in Copen-
hagen (Denmark) via advertisement in a local newspaper. Subjects were
prescreened via telephone or face-to-face interview. Straight anterioreposte-
rior radiographs of both knees were obtained, with the patient standing. An ex-
perienced reader classiﬁed each knee for severity ofOAusing theKellgren and
Lawrence (KL) grading system, with scores from 1 to 452. Inclusion criteria
were age between 50 and 70 years with radiographic evidence of bilateral
knee OA (KL-score of 1e4) who met the American College of Rheumatology
(ACR) clinical53 and radiographic classiﬁcation criteria.
At inclusion a medical doctor examined the patients and established
a medical record for each patient. Normal kidney and liver function was ver-
iﬁed by analyses of serum creatinine and alkaline phosphatase. All patients
were negative for rheumatoid factor and their serum uric acid was normal.
Patients were excluded if they had severe health problems such as cardio-
vascular disease, active cancer, diabetes, kidney or liver diseases, excess
alcohol use (>21 alcoholic drinks per week) or severe overweight
(BMI> 35). Furthermore none of the subjects had any history of injury or op-
eration in the knee, planned kneeejoint replacement, other rheumatologic
diseases, previous gastric ulcer, and none were allergic to the contents of
ibuprofen or glucosamine. Being physically active (bicycling or walking)
was not an exclusion criterion, but none of the subjects trained regularly or
performed strength training prior to the inclusion in the present study. Prior
to the study, all subjects provided written informed consent to participate inthe study. The experimental protocol was approved by the local Ethical Com-
mittee for Copenhagen and Frederiksberg Communities (KF 01-189/04). All
procedures followed were in accordance with the ethical standards of the
Helsinki Declaration of 1975, as revised in 2000.MEDICATIONFour patients from each group were previously treated with NSAID. Seven
patients from the glucosamine-group and ﬁve from both the ibuprofen and
placebo-group had previously taken glucosamine. They were instructed to
stop the intake at least 1 month before the study began. Patients were ran-
domly assigned to one of three medication groups. They were administered
glucosamine (n¼ 12), NSAID (n¼ 12) or placebo (n¼ 12). The administra-
tion of placebo and glucosamine was started 4 weeks before the training,
but active NSAID treatment was initiated only 1 week before (Fig. 1). We
chose to initiate the administration of glucosamine 4 weeks before training
in order to ensure that glucosamine levels were adequate. Furthermore, it
has been shown that ibuprofen works more quickly than glucosamine, which
has to be given at least 2 weeks before you can expect a potential effect on
OA symptoms54,55. Subjects in the glucosamine-group were given glucos-
amine sulphate tablets (Ferrosan) of 500 mg three times a day and subjects
in the NSAID group were given tablets of 600 mg of ibuprofen (Nycomed)
twice a day. Placebo tablets were identically supplied and formulated as
the glucosamine or ibuprofen tablets except that they contained no medicine.
The treatment was blinded to the patients, so that all subjects were supplied
the same amount of pills (ﬁve a day) that had similar appearance. To ensure
compliance, the subjects returned the empty packages every week to a lab
technician not involved in other parts of the study. For further control, NSAID
levels in the blood were traced in the beginning of the training period, as well
as after 6 and 12 weeks. If any of the patients experienced severe pain dur-
ing the training period, they were allowed to take ‘‘rescue medicine’’ 50 mg
tramadol (synthetic, monoagonistic opioid), which unlike NSAID does not in-
ﬂuence prostaglandin synthesis. Alternatively the subjects were offered
acupuncture.TRAINING AND TESTINGAll three groups of patients performed a strength training program with
both legs for 12 weeks. The program consisted of bilateral progressive
strength training of the leg muscles with focus on the quadriceps muscles.
Training was carried out over three sessions per week, 36 sessions in total,
with a minimum of 30 sessions required for all subjects (representing a min-
imum of 83.3% participation). After a 10 min warm up on a stationary bicycle,
the subjects performed sitting knee extension and leg-press exercises with
one leg at a time in adjustable leg-press and knee-extension machines
(Technogym International). Physiotherapists or physical educated personnel
attended every training session and instructed the subjects performing the
exercises. Training intensity was changed from 15 to 8 repetition maximum
(RM) (4 sets 12e8 repetitions) from week 0 to 7 to avoid injuries, and was
thereafter maintained at 8 RM (4e5 sets 8 repetitions) for the remaining
training period. (Deﬁnition: 8 RM refers to the maximum load an individual
can exert in an exercise no more or no less than eight times with his/her max-
imal effort.) The relative workload was 70e80% of 1 RM through all 12
weeks, and training load was adjusted on a weekly basis. Furthermore, 5
RM strength tests were performed in the ﬁrst week of the study, after 6
weeks, and in the last week of the training study (Fig. 1). 5 RM tests were
performed both in the knee extension and in the leg-press machine. After ev-
ery strength training session, subjects were given a 200 ml chocolate milk
drink (Matilde classic, Arla), which is known to ensure optimal muscle protein
synthesis56.URINE AND BLOOD SAMPLINGBefore and after the 12-week strength training blood and urine samples
were collected from the subjects (Fig. 1), who were asked to limit their
Fig. 2. Progress of participants throughout the trial.
36 S. G. Petersen et al.: Glucosamine alters cartilage turnoverphysical activity before sampling. No formal training was carried out for a min-
imum of 48 h prior to blood and urine sampling. On the day of the sampling
the subjects met in the laboratory after having consumed a standardized,
regular breakfast. Venous blood samples were drawn and serum prepared
in a standard way and stored at 80C until analysis. The subjects them-
selves collected the urine in the morning (ﬁrst morning void), before they
met in the laboratory. The urine samples were stored at 20C until
measurement.COMP AND CTX-II ANALYSISSerum COMP was measured by a sandwich ELISA (COMPELISA; Ana-
Mar Medical AB, Lund, Sweden). Urinary CTX-II was measured by a compet-
itive ELISA (Cartilaps, Nordic Bioscience, Herlev, Denmark)57. Urinary
CTX-II measurements were corrected for urinary creatinine measured by
a standard colorimetric assay using a kit from Konelab (Espoo, Finland).
Biomarkers were analyzed in duplicate in ELISA by trained lab
technicians.STATISTICAL ANALYSISStatistical Analysis System (SAS, Version 9.2, SAS Institute, Cary, NC)
was used to analyze the data. Analyses were performed on the log-trans-
formed dependent variable (marker-level) to improve approximation of theTable I
Baseline characteristics of participants in the three groups
Glucosamine Ibuprofen Placebo
Sample size 12 11 12
Gender 7F/5 M 7F/4 M 7F/5 M
Age (years) 62.2 3.4 61.7 5.2 63.1 4.7
Body weight (kg) 78 14 83 17 82 14
Height (cm) 168 11 172 9 169 9
BMI (kgm2) 27.3 3.3 27.9 3.9 28.3 3.2
X-ray (KL-score) 2.5 0.8 2.3 1.0 2.2 1.0
COMP baseline
(U/L)
13.6/O 1.3 14.3/O 1.3 13.8/O 1.4
CTX-II baseline
(ng/mmol)
514.3/O 2.2 327.2/O 1.6 304.6/O 1.6
Data for continuous measures are meanSD. Data for bio-
markers are backtransformed factor means /O factor SD.normal distribution. To evaluate the combined effect of training and treatment
over time within each group, paired t tests were used. The change in log-
transformed marker-level from pre to post treatment was compared between
groups using an analysis of variance model with treatment as factor and log-
transformed pre-treatment marker-level as a covariate. Treatment differ-
ences were estimated from the model and 95% conﬁdence intervals were
calculated. The results in the text are expressed as relative changes ob-
tained by back-transforming the estimates from the model.
P values< 0.05 were considered signiﬁcant, and all tests were two tailed.Results
The total number of persons prescreened via telephone
or face-to-face interview during the recruitment period was
181 (Fig. 2). Of these, 36 were randomized, and 145 wereFig. 3. Leg-press 5 RM tests. All groups increased signiﬁcantly in
strength (***P 0.001).
Fig. 4. Knee extension 5 RM tests. All groups increased signiﬁ-
cantly in strength (**P 0.01, ***P 0.001).
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most common reason for disqualiﬁcation were lack of
knee OA on X-ray or unilateral OA (28%), major health
problems that met exclusion criteria (22%), previous knee-
trauma or operation (19%), age under 50 or over 70
(10%), other rheumatologic diseases (5%), regular training
(8%), previous gastric ulcer (4%) or intolerance/allergy to-
wards contents of glucosamine or ibuprofen (4%). Of the
36 randomized participants, 35 subjects completed the
study. The one subject belonging to the ibuprofen group
withdrew for personal reasons. During the analysis for se-
rum COMP, one blood sample (pre-treatment) was missing
on another subject from the Ibuprofen group, but this was
not the case when analyzing for CTX-II. There were no dif-
ferences between the groups with respect to subject char-
acteristics at the inclusion of the study (Table I).
All participants were physically active on a light to moder-
ate level (bicycling or walking) but none of them trained reg-
ularly or performed strength training prior to inclusion in the
present study.
Upon completion of the training period, there was no differ-
ence between the groups with regard to participationFig. 5. Levels of serum COMP (on a logarithmic scale) pre and post 12-w
We observed a statistical signiﬁcant decrease in serum C(95 1%) in training sessions. No patient reported any side
effects of the project drugs during the study. The blood sam-
ples that were analyzed for ibuprofen, revealed that all pa-
tients in the ibuprofen group took their medication as they
were instructed, and none from the two other groups took
any ibuprofen during the project. Three subjects (two from
the placebo-group, and one from the ibuprofen group) used
the rescue medicine tramadol for a short period (<5 days)
during the study, two because of training related pain, and
one because of tooth-pain. Furthermore, two persons were
treated with acupuncture (both of them belonged to the ibu-
profen group, one of them was also treated with tramadol).MUSCLE STRENGTHFollowing 12 weeks of strength training, all three groups
increased their muscle strength (P< 0.001) as measured
in the 5 RM tests in both the leg-press (Fig. 3) and the
knee-extension machine (Fig. 4).BIOMARKERSAfter the 12 weeks of muscle strength training, there was
a 13% decrease in serum COMP levels (P¼ 0.012) in the
glucosamine-treated group (Fig. 5). In contrast, no signiﬁ-
cant change in serum COMP levels was seen after the
training period neither in the placebo nor in the ibuprofen
group. Glucosamine reduced COMP signiﬁcantly compared
to the changes with both placebo and ibuprofen; the mean
reduction with glucosamine was 13% vs placebo (95% con-
ﬁdence interval: 24e1%, P¼ 0.0378) and 17% vs ibuprofen
(95% conﬁdence interval: 28e4%, P¼ 0.0122). There was
no statistically signiﬁcant difference between ibuprofen
and placebo (Table II).
Regarding CTX-II levels in our study, no signiﬁcant
changes were observed in any of the three experimental
groups (Fig. 6). Interestingly, however, patients from the glu-
cosamine-treated group with high baseline CTX-II levels
(above normal average þ1 standard deviation) responded
with slightly reducedCTX-II levels after the training (P¼ 0.1).Discussion
The present experiment demonstrated that in response to
a period of muscle strength training (12 weeks) muscleeek of strength training. Each line represents an individual patient.
OMP levels in the glucosamine-group (P¼ 0.012).
Table II
Mean effects of treatments, with the log-transformed pre-treatment
value of the dependent marker as a covariate
Glucosamine vs
placebo
Ibuprofen vs
placebo
Glucosamine vs
ibuprofen
COMP 13 (24 to 1)* 4 (10 to 20) 17 (28 to 4)*
CTX-II 38 (19 to 135) 39 (16 to 132) 1 (42 to 69)
Data are mean percent, in parentheses 95% conﬁdence
intervals.
*Star signiﬁes the presence of statistically signiﬁcant treatment
effect, here seen as a difference in serum levels of COMP between
glucosamine and placebo (P¼ 0.038) and between glucosamine
and ibuprofen (P¼ 0.012).
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individuals were treated with NSAID (ibuprofen), glucos-
amine or placebo (Figs. 2 and 3). Training per se did not
seem to induce changes in circulating levels of markers for
cartilage degradation, which is in line with previous ﬁnd-
ings25. Analyses of the speciﬁc medication-effect, revealed
that glucosamine decreased COMP signiﬁcantly compared
to treatment with placebo or ibuprofen. Clearly, from these
data it is not possible to elucidatewhether this reduction in se-
rum COMP levels transforms into a better clinical status in
these patients. From earlier ﬁndings it is doubtful as to
whether glucosamine per se has any beneﬁcial effect on
OA symptoms42. Whereas some studies show a beneﬁcial
clinical effect of glucosamine per se42,58e60 others have
found no difference between glucosamine treatment and pla-
cebo groups61e63. A general critique of some of the previous
studies has been that they were small, had poor design and
ﬂaws in the data analysis, and that there has been a potential
for sponsor bias64e66. Furthermore, to our knowledge only
one study has previously tried to combine physical training
with glucosamine in kneeOA patients62. In that study, no sig-
niﬁcant effect of the treatment was found after 6 months of
combined treatment, either on function, pain or mobility62.
Muscle strength in that study showed similar alterations, in
that they did not ﬁnd any major difference between glucos-
amine and placebo groups. Post hoc analysis from the study
ofMessier, did, however, indicate thatmore pill-compliantOA
subjects had more improvements in pain and mobility than
less compliant individuals. Taken together, our present ﬁnd-
ings suggest an effect by glucosamine on the response of
the OA cartilage to a period of joint loading in humans with
knee OA.Fig. 6. Urine CTX-II levels (on a logarithmic scale) pre and post 12-wee
signiﬁcant alterations in CTX levels weThere is evidence in vitro that physiologic concentrations
of glucosamine can induce a diminished proteolytic activity
of matrix metalloproteinase and increased synthesis of ag-
grecan67. Furthermore, some animal studies have shown
that glucosamine can stimulate the regeneration of carti-
lage68,69. It is thus possible that the altered COMP levels
we now observe reﬂect an altered cartilage metabolism,
and if sustained over a long time this might inﬂuence joint
morphology and clinical presentation.
Regarding CTX-II levels in our study, no signiﬁcant
changes were observed in any of the three experimental
groups. Interestingly, however, patients from the glucos-
amine-treated group with high baseline CTX-II levels re-
sponded with slightly reduced CTX-II levels after the
training. This is in agreement with previous ﬁndings, where
glucosamine treatment decreased se-CTX-II more in OA
patients with high cartilage turnover than in patients with
a lower cartilage turnover33. Thus, a higher turnover of car-
tilage components may be associated with a higher likeli-
hood of response to treatment with glucosamine.
Acute exercise has been shown to inﬂuence circulating
levels of COMP25,31, and even moderate amounts of dy-
namic exercise like walking or gymnastics have been
shown to lead to 10e20% elevated circulating levels of
COMP immediately after the event, both in healthy individ-
uals31 and in OA patients25. It is, however, important to
note that serum levels of COMP are normalized already
30 min after exercise25,31 implying that the effect was rather
an effect of clearance than a metabolic effect. However, the
patients in our study were investigated at least 24 h after the
last training bout, and it is unlikely that acute exercise inﬂu-
enced our results. Only after very extreme exercise bouts
like a marathon run in healthy individuals, was up to 24 h re-
quired for normalization of COMP levels30. Furthermore, our
sampling of blood in the OA patients was performed at the
same time of the day, to avoid any inﬂuence of diurnal var-
iation in COMP concentrations70,71. In the present study
only circulating levels of COMP were determined, and exact
evaluation of changes in the joint is therefore not possible.
However, as cartilage is a major contributor to circulating
COMP levels72,73, the reduction in COMP levels most likely
represents reduced degradation of cartilage in the loaded
joints. It could, however, also represent changes in extra-
cartilage degradation of COMP, since COMP is not only
found in cartilage, but also in tendon, ligaments, interverte-
bral discs, etc74. However, it is shown that the concentration
of COMP in these tissues is very low in compare toks strength training. Each line represents an individual patient. No
re observed in any of the groups.
39Osteoarthritis and Cartilage Vol. 18, No. 1cartilage74, so even though there might have been a small
change in concentration of COMP in the extra-cartilage tis-
sues, it constitutes a very small amount of the circulating
COMP levels. Finally, an alternative, which cannot be ruled
out is that our ﬁndings may indicate, that the synthesis and
release of newly synthesized COMP-molecules is de-
creased with glucosamine treatment.
In conclusion, glucosamine modiﬁed the effect of physical
strength training in elderly OA patients, in that serum COMP
was signiﬁcantly reduced over the 12-week training period
when glucosamine was added to the training regimen.
This suggests an effect of glucosamine on the response
of the OA cartilage to a period of joint loading in humans
with knee OA.Conﬂict of interest
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